EBV‐negative and ‐positive burkitt cell lines variably express receptors for B‐cell activation and differentiation

Abstract

The expression of receptors for proliferation and differentiation factors was analyzed by indirect immunofluorescence on 29 Burkitt lymphoma (BL) cell lines previously classified into 3 groups on the basis of their reactivity with 8 monoclonal antibodies (MAbs), including anti-CALLA, BL13 and TU1. BL13 and HB5 antibodies recognize different epitopes of the EBV/CR2 receptors. The determinant recognized by BL13 has been previously shown to be expressed only on cell lines of the first two groups, supposed to derive from the germinal center and to be negative on a third group of lines of putative BM origin and established from sporadic cases of BL. In contrast, and as expected from its reactivity on normal B cells in the BM or in the lymph nodes, HB5 antibody reacts with all BL lines except one. The receptor for transferrin is expressed on the 29 lines. Two new MAbs, Bac-1 and B1H5, could recognize respectively receptors for BCGF1 and BCGF2. Bac-1 reacts with 15 of 17 BL lines belonging to the first two groups and 7 of 12 BL lines of the third group; 14 of 15 EBV + lines express Bac-1. No BL line expresses B1H5. The IL2 receptor is weakly expressed on 5 EBV + cell lines and one EBV (-) line. All delta are BCGF1-positive. The almost constant expression of BCGF1 receptor on EBV + cell lines is the only strict relation between the expression of receptors for growth factors and their characteristics (i.e. EBV association, translocation, ethnic origin and clinical presentation). The maturation stage or the origin of BL cell lines in relation to the expression of growth factor receptors and the functional significance of these receptors will be discussed.

aberrant expression of HLA Class‐I antigens in burkitt lymphoma cells

“…BL lines that have been propagated in vitro for a prolonged period of time are heterogeneous with regard to expression of B-cell activation and differentiation markers (Rowe et al, 1986;Favrot et al, 1986) and, in the case of EBV-carrying BLs, viral antigens (Rowe et al, 1987). EBV-negative BL lines, and some of the EBV-positive ones, maintain the phenotype of the biopsy cells characterized by high expression of CDlO and CD77, absence of B-cell activation markers and down-regulation of all EBV-encoded antigens except EBNA-1 (group-I BLs).…”

Isolation of a normal B cell subset with a Burkitt‐like phenotype and transformation in vitro with Epstein‐Barr virus

“…A major obstacle in this regard has been the lack of any clear definition of the particular B cell subset from which the tumour is derived. Many attempts have been made to define the cell surface phenotype of the tumour by analyzing BL cell lines, often long after their establishment in vitro, but these studies have invariably found that such lines display any one of a range of different phenotypes (Nilsson and Klein, 1982;Favrot et al, 1984;Ehlin-Henriksson and Klein, 1984;Favrot et al, 1986;Cohen et al, 1987). Accordingly this has fostered the view that BL can arise from target cells at any one of several positions along the B cell differentiation pathway.…”

In vitro culture of B-lymphocytes derived from epstein-barr-virus-associated posttransplant lymphoproliferative disease: Cytokine production and effect of interferon-alpha

“…The positivity for CD21 demonstrates, in addition, the presence of Epstein-Barr virus receptors on these cells. The CD77 marker has been hitherto described in Burkitt's lymphoma (BL) cell lines, but not lymphoblastoid cell lines (LCLs) growing out of healthy individuals seropositive for EpsteinBan" virus (Favrot et al, 1986;Rooney et al, 1986;Cohen et al, 1987;Avila-Carino et al, 1991). However, we found that CD77 antiserum obtained from Serotech reacted also with LCLs obtained from the peripheral blood of two immunosuppressed organ transplant recipients without posttransplant lymphoproliferative disease.…”